[DOI] [PubMed] [Google Scholar] 89.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al
Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food
Whether they are using semaglutide GLP-1 for its appetite-suppressing effects or Zepbound to manage food cravings, Dr
Sources: 1
As discussed above, endogenous GLP-1 is rapidly degraded by DPP-4, whereby it loses its insulinotropic activity, and preventing this degradation results in increased intact GLP-1 levels, improved pancreatic islet responses (enhanced insulin and suppressed glucagon levels) and beneficial effects on glucose homeostasis

To qualify, you need to meet one of the following requirements when starting GLP-1 treatment: A BMI (body mass index) of 35 or higher A BMI between 30 and 34.99, with one or more additional conditions: Diastolic heart failure Uncontrolled high blood pressure/hypertension Chronic kidney disease, stage 3a or higher Prediabetes Previous heart attack or stroke Blocked arteries in arms or legs with symptoms A BMI between 27 and 29.99, with one or more additional conditions: Prediabetes Previous heart attack or stroke Blocked arteries in arms or legs with symptoms Medicare beneficiaries who have sleep apnea, diabetes or fatty liver disease can't access the program, but their Medicare Part D insurance might cover their GLP-1s separately based on those diagnoses